leisure time -WSS

leisure time

author：explore 2025-09-03 09:34:15 - browse：9

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA sets aggressive timeline for overhauling inspection procedures

hotspot

WSS

JPM: CVS says Medicare Advantage patients are impacting profits

Dana Farber says 6 studies to be retracted and 31 corrected

To bolster infectious disease surveillance, genomics powerhouses team up

Why psychiatrists like me stop taking insurance

Dog Aging Project founders on what lies ahead after losing funding

How a scoliosis diagnosis changed the life of one young dancer

entertainment

leisure time

knowledge

Virginia high school admissions case could be legal follow

A single drug, study failures leave Anavex with nothing but cash

Anesthesiologist group: stop taking Ozempic before surgery

Medicare drug price lawsuits could be good politics for Biden

Malaria cases in Florida and Texas: Here’s what you need to know

Microsoft launches AI tool for clinical documentation through Epic

Cancer drug shortages should be causing more outrage

Head of FDA's diagnostics center, who led through Covid, retires

Alkermes shareholders re

Printout prescription drug information shouldn’t go digital

explore

Feng Zhang, Grail founder join forces on new gene editing startup

Maisha Meds is a PBM, but don't call it that

Burning questions for the 2024 JPM Healthcare Conference

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Prior authorization reform is both possible and imperative

Why psychiatrists like me stop taking insurance

hotspot

hotspot

entertainment

explore